SARASOTA, FL -- (MARKET WIRE) -- 01/26/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company and Harvard University have entered into a sponsored research and a field-exclusive licensing agreement. Under the agreement, DNAPrint Genomics, Inc. will sponsor further development in the Laboratory for Translational Research (LTR) at Harvard Medical School of a diagnostic test devised in the Laboratory to target early identification of the population at risk of developing vascular diabetic complications. The Company also will conduct work directed toward its eventual commercialization of the test.

Diabetes is the number one cause of renal transplants, blindness and leg amputations. These are all vascular (blood vessel) complications of diabetes and are the most serious and burdensome effects of the disease for diabetic patients. Treatment of these complications of diabetes consumes 10-15% of the overall US health budget. Therefore, early detection of the diabetic population at risk is a major public health priority as set out by the National Heart Lung and Kidney Institute of the National Institutes of Health in the 1990s. Dr. Jose Halperin, head of the LTR, and members of his research group discovered that a molecule -- called CD59 -- which is a regulator of the complement system, appears to be a key player in how small blood vessels are damaged during the spikes in blood glucose levels that are common in diabetic individuals. Continuous damage to these microvessels is the underlying cause of the kidney, nerve and heart disease that more than 60% of diabetic patients suffer over a lifetime. This discovery of a molecule that is a hallmark of such vessel damage will enable DNAPrint Genomics, Inc. to develop a test to identify even very early stages of microvascular complications.

"Unfortunately, by the time patients are diagnosed with a major complication of diabetes, it may be too late for effective therapy by most available medications and changes in life style," said Dr. Hector Gomez, Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary of DNAPrint Genomics, Inc. This collaboration will further the development of new diagnostic tests that will help physicians and healthcare providers re-direct predisposed patients to healthier lifestyle changes and perhaps even some day, medications to help slow down or prevent the onset of vascular diabetic complications.

"This well advanced technology licensed by DNAPrint Genomics Inc. was developed with support from the National Institutes of Health, which funded much of the early discovery work. We are pleased to have the opportunity to sponsor research that will further develop and eventually commercialize this important diagnostic test that could significantly improve the management of diabetes," said Richard Gabriel, CEO and President of DNAPrint Genomics, Inc.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
CEO and President
941 366-3400

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848